SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Relapsing Remitting Multiple SclerosisPrimary Progressive Multiple SclerosisSecondary Progressive Multiple Sclerosis

Interventions

DRUG

Ixazomib (NINLARO®) capsules / Matching placebo capsules

Participants will be treated for a maximum of 24 months

Trial Locations (1)

RECRUITING

Royal London Hospital, Barts Health NHS Foundation Trust, London

All Listed Sponsors

collaborator

Takeda Pharmaceuticals International, Inc.

INDUSTRY

lead

Queen Mary University of London

OTHER

NCT03783416 - SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis | Biotech Hunter | Biotech Hunter